Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial

Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial

Abstract Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease. 611, a humanized monoclonal antibody, selectively targets the interleukin (IL)-4 receptor alpha, thereby inhibiting the signaling of both interleukin (IL)-4 and IL-13. This phase 2 study aimed to evaluate the effica...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan Zhao, Litao Zhang, Liming Wu, Xinsuo Duan, Chao Ji, Rong Xiao, Mingkai Ji, Lunfei Liu, Bin Yang, Guohong Hu, Yanyan Feng, Jianjian Zhu, Jianguo Li, Yangfeng Ding, Haomin Huang, Qinghong Zhou, Yuyu Xu, Jianzhong Zhang
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-03-01
Series:Dermatology and Therapy
Subjects:
Atopic dermatitis
Chinese patients
611
Interleukin-4 receptor alpha
Eczema area
Severity index
Online Access:https://doi.org/10.1007/s13555-025-01368-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01368-4

Similar Items